MUMBAI, India, June 30 -- Intellectual Property India has published a patent application (202641074776 A) filed by Vellore Institute Of Technology on June 17, 2026, for “a Pharmaceutical Composition For Treatment Of Epidermal Growth Factor Receptor (egfr)-Mutant Non-Small Cell Lung Cancer”.
Inventors include Dr. Sudandiradoss C; Poobana Dharmalingam; and Alisha Martha Joseph.
The application for the patent was published on June 26, 2026, under issue no. 26/2026.
Abstract: The present invention relates to pharmaceutical compositions and methods for treating epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), particularly NSCLC associated with treatment-resistant EGFR mutations. The invention provides a pharmaceutical composition comprising O-(2- morpholinoethyl)-honokiol or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, tautomer, polymorph, prodrug, or derivative thereof in combination with BLU-945 or a pharmaceutically acceptable salt thereof. The O-(2-morpholinoethyl)-honokiol is a morpholinoethyl-substituted derivative of honokiol designed to improve molecular stability, bioavailability, and interaction capability with mutant EGFR targets. The composition is configured to inhibit EGFR-mediated signaling pathways and overcome resistance associated with EGFR mutations including L858R, T790M, C797S, and combinations thereof. In particular embodiments, the composition is effective against triple-mutant EGFR comprising L858R/T790M/C797S mutations. The invention further provides a method for treating EGFR-mutant NSCLC by administering a therapeutically effective amount of the composition to a subject in need thereof. The combination exhibits enhanced target-binding interactions and improved inhibition of mutant EGFR activity relative to conventional honokiol-based therapies, thereby providing a promising therapeutic approach for overcoming resistance mechanisms associated with advanced EGFR-targeted cancer treatment. Fig 1 to 4.
Disclaimer: Curated by HT Syndication.
